Creo Medical Group (CREO): Sale of 49% Creo Medical SL stake

This situation live

£48m · 11.2p · −1% since the first step

22 May 2026 · Non-binding LOI signed; due diligence pending · −5% until the next step The parties are targeting completion within three months.

22 May 2026 · Non-binding agreement; completion targeted within three months · −5% until the next step the Company is targeting completion of the CME Stake Disposal within three months.

28 Jul 2026 · Completion expected during Q3-26 · −24% until the next step Creo continues to progress the CME Stake Disposal, with completion expected during Q3-26.

Disposal of a part (break-up)

Sale of 49% Creo Medical SL stake

Delayed; binding terms now expected Q4 2026

Next: Agree binding terms for CME stake sale

Every step · 5

22 May 2026 Non-binding LOI signed; due diligence pending – The parties are targeting completion within three months. ↗
22 May 2026 Non-binding agreement; due diligence pending – has entered into a non-binding agreement regarding the potential sale of its 49% interest in CME for a consideration broadly in line with its carrying value... ↗
22 May 2026 Non-binding agreement; completion targeted within three months – the Company is targeting completion of the CME Stake Disposal within three months. ↗
28 Jul 2026 Completion expected during Q3-26 – Creo continues to progress the CME Stake Disposal, with completion expected during Q3-26. ↗
30 Sep 2026 Delayed; binding terms now expected Q4 2026 – The Board’s current expectation is that binding terms will be agreed during Q4 2026, and further updates will be provided in due course. ↗

What is happening

Creo Medical Group: Sale of 49% Creo Medical SL stake – Delayed; binding terms now expected Q4 2026. ['Delayed; binding terms now expected Q4 2026']

In short: Creo sold 51% of CME in February 2025 and signed a non-binding agreement in May 2026 to sell the remaining 49%. On 28 July completion was expected in Q3-26. The 30 September interims say the sale is taking longer than expected, with only binding terms now expected in Q4 2026. Other potential acquirers are in talks alongside the original purchaser.
Announced: 22 May 2026 · Non-binding LOI signed; due diligence pending
Latest: 30 Sep 2026 · Delayed; binding terms now expected Q4 2026
Price: Indicative EV in line with 31 December 2025 carrying value; cash-free, debt-free (May 2026)
Status: Non-binding heads of terms; binding terms now expected during Q4 2026 (previously completion in Q3-26)
Earlier sale: 51% sold in FY25: £24.7m net cash, £26.2m profit on disposal
CME dividend: £1.6m received post period end
Buyer: Original proposed purchaser plus other potential acquirers in talks
Timetable: Company targets completion within three months
Placing link: Placing is not conditional on the CME sale and will complete before any binding agreement
Funding link: Delay creates material uncertainty in the going concern statement

Agree binding terms for CME stake sale.

Briefing Pro

What it does, how it got here, what management promised and delivered – written from its own announcements.

From the company's own announcements. Not investment advice.

Also at Creo Medical Group 1 open